Proteogenomic analysis shows the biological downstream pathways leading by driven mutations of gliomas, such as IDH1, TP53, and EGFR. The comparative analysis illustrates the distinctive features of GBMs and LGGs, indicating inhibiting CDK2 might serve as a promising drug for GBMs. This evidence concerns the gene TP53 and central nervous system cancer.